Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin Alfa in Alcohol-related Liver Disease (ALD)
NCT07791043Phase 2Recruiting
- Sponsor
- GSK
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 2
01
Overview
A Phase 2 trial of efimosfermin in alcoholic liver disease (ALD), sponsored by GSK. Started Aug 2026; status: recruiting.
02
Drugs
efimosfermin
03
Conditions
alcoholic liver disease (ALD)
Beyond the preview
Go deeper on NCT07791043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791043.